MedTrace Logo

Intravenous Versus Subcutaneous Administration of Low Molecular Weight Heparin for Thromboprophylaxis in Critically Ill Patients

NCT04982055 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-07-29

No results posted yet for this study

Summary

Objective: To compare the pharmacokinetic profiles of intravenous versus subcutaneous route of administration of LMWH for thromboprophylaxis in critically ill patients

Conditions

  • Critical Illness

Interventions

DRUG

Nadroparin (intravenous Infusion)

Intravenous route of administration over a 4-hours infusion of nadroparin 3800 IU

DRUG

Nadroparin (subcutaneous group)

Subcutaneous route of administration of nadroparin 3800 IU

Sponsors & Collaborators

  • Clinique Saint Pierre Ottignies

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-08
Primary Completion
2020-12-31
Completion
2020-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04982055 on ClinicalTrials.gov